227 related articles for article (PubMed ID: 34990619)
1. iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II.
Hong J; Cheng YS; Yang S; Swaroop M; Xu M; Beers J; Zou J; Huang W; Marugan JJ; Cai X; Zheng W
Exp Cell Res; 2022 Mar; 412(1):113007. PubMed ID: 34990619
[TBL] [Abstract][Full Text] [Related]
2. Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II.
Rybová J; Ledvinová J; Sikora J; Kuchař L; Dobrovolný R
J Inherit Metab Dis; 2018 Mar; 41(2):221-229. PubMed ID: 29168031
[TBL] [Abstract][Full Text] [Related]
3. Induced Pluripotent Stem Cells for Disease Modeling and Evaluation of Therapeutics for Niemann-Pick Disease Type A.
Long Y; Xu M; Li R; Dai S; Beers J; Chen G; Soheilian F; Baxa U; Wang M; Marugan JJ; Muro S; Li Z; Brady R; Zheng W
Stem Cells Transl Med; 2016 Dec; 5(12):1644-1655. PubMed ID: 27484861
[TBL] [Abstract][Full Text] [Related]
4. Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells.
Huang W; Cheng YS; Yang S; Swaroop M; Xu M; Huang W; Zheng W
Exp Cell Res; 2021 Oct; 407(1):112785. PubMed ID: 34411609
[TBL] [Abstract][Full Text] [Related]
5. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome.
Arguello A; Meisner R; Thomsen ER; Nguyen HN; Ravi R; Simms J; Lo I; Speckart J; Holtzman J; Gill TM; Chan D; Cheng Y; Chiu CL; Dugas JC; Fang M; Lopez IA; Solanoy H; Tsogtbaatar B; Zhu Y; Bhalla A; Henne KR; Henry AG; Delucchi A; Costanzo S; Harris JM; Diaz D; Scearce-Levie K; Sanchez PE
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622797
[TBL] [Abstract][Full Text] [Related]
6. A method for measuring disease-specific iduronic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice.
Shimada Y; Wakabayashi T; Akiyama K; Hoshina H; Higuchi T; Kobayashi H; Eto Y; Ida H; Ohashi T
Mol Genet Metab; 2016 Feb; 117(2):140-3. PubMed ID: 26051019
[TBL] [Abstract][Full Text] [Related]
7. Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease.
Vu M; Li R; Baskfield A; Lu B; Farkhondeh A; Gorshkov K; Motabar O; Beers J; Chen G; Zou J; Espejo-Mojica AJ; Rodríguez-López A; Alméciga-Díaz CJ; Barrera LA; Jiang X; Ory DS; Marugan JJ; Zheng W
Orphanet J Rare Dis; 2018 Sep; 13(1):152. PubMed ID: 30220252
[TBL] [Abstract][Full Text] [Related]
8. Neural stem cells for disease modeling of Wolman disease and evaluation of therapeutics.
Aguisanda F; Yeh CD; Chen CZ; Li R; Beers J; Zou J; Thorne N; Zheng W
Orphanet J Rare Dis; 2017 Jun; 12(1):120. PubMed ID: 28659158
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome).
Sohn YB; Cho SY; Park SW; Kim SJ; Ko AR; Kwon EK; Han SJ; Jin DK
Orphanet J Rare Dis; 2013 Mar; 8():42. PubMed ID: 23497636
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
[TBL] [Abstract][Full Text] [Related]
12. Modelling the neuropathology of lysosomal storage disorders through disease-specific human induced pluripotent stem cells.
Kobolák J; Molnár K; Varga E; Bock I; Jezsó B; Téglási A; Zhou S; Lo Giudice M; Hoogeveen-Westerveld M; Pijnappel WP; Phanthong P; Varga N; Kitiyanant N; Freude K; Nakanishi H; László L; Hyttel P; Dinnyés A
Exp Cell Res; 2019 Jul; 380(2):216-233. PubMed ID: 31039347
[TBL] [Abstract][Full Text] [Related]
13. Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses.
Sima N; Li R; Huang W; Xu M; Beers J; Zou J; Titus S; Ottinger EA; Marugan JJ; Xie X; Zheng W
Orphanet J Rare Dis; 2018 Apr; 13(1):54. PubMed ID: 29631617
[TBL] [Abstract][Full Text] [Related]
14. Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural studies on iduronate-2-sulfatase.
Kosuga M; Mashima R; Hirakiyama A; Fuji N; Kumagai T; Seo JH; Nikaido M; Saito S; Ohno K; Sakuraba H; Okuyama T
Mol Genet Metab; 2016 Jul; 118(3):190-197. PubMed ID: 27246110
[TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report.
Muenzer J; Lamsa JC; Garcia A; Dacosta J; Garcia J; Treco DA
Acta Paediatr Suppl; 2002; 91(439):98-9. PubMed ID: 12572850
[TBL] [Abstract][Full Text] [Related]
16. Auditory characteristics and therapeutic effects of enzyme replacement in mouse model of the mucopolysaccharidosis (MPS) II.
Hong SH; Chu H; Kim KR; Ko MH; Kwon SY; Moon IJ; Chung WH; Cho YS; Kim CH; Suh MW; Choi EW; Sohn YB; Park SW; Kim SH; Cho SY; Ko AR; Jin DK
Am J Med Genet A; 2012 Sep; 158A(9):2131-8. PubMed ID: 22847837
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease).
Kubaski F; Vairo F; Baldo G; de Oliveira Poswar F; Corte AD; Giugliani R
Curr Pharm Des; 2020; 26(40):5100-5109. PubMed ID: 33138761
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome).
Gusarova VD; Smolov MA; Lyagoskin IV; Degterev MB; Rechetnik EV; Rodionov AV; Pantyushenko MS; Shukurov RR
BioDrugs; 2023 May; 37(3):375-395. PubMed ID: 37014547
[TBL] [Abstract][Full Text] [Related]
20. Efficient engraftment of genetically modified cells is necessary to ameliorate central nervous system involvement of murine model of mucopolysaccharidosis type II by hematopoietic stem cell targeted gene therapy.
Miwa S; Watabe AM; Shimada Y; Higuchi T; Kobayashi H; Fukuda T; Kato F; Ida H; Ohashi T
Mol Genet Metab; 2020 Aug; 130(4):262-273. PubMed ID: 32631737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
